Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1993 2
1994 1
1995 1
1998 1
2003 1
2004 2
2006 1
2007 4
2008 2
2009 2
2010 2
2011 3
2012 4
2013 3
2014 3
2015 1
2016 3
2017 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Syver
Page 1
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH. Eskelund CW, et al. Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5. Br J Haematol. 2016. PMID: 27378674
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Geisler CH, et al. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025. Epub 2008 Jul 14. Blood. 2008. PMID: 18625886 Free PMC article. Clinical Trial.
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF. Bogen B, et al. Eur J Immunol. 1995 Nov;25(11):3079-86. doi: 10.1002/eji.1830251114. Eur J Immunol. 1995. PMID: 7489746
Mice made transgenic for a lambda 2(315)-specific alpha beta T cell receptor have been demonstrated to be specifically resistant against a tumor challenge with the MOPC315 (alpha,lambda 2(315)) plasmacytoma (Lauritzsen, G. F., Weiss, S., Dembic, Z. and Bogen, B., Proc. Nat …
Mice made transgenic for a lambda 2(315)-specific alpha beta T cell receptor have been demonstrated to be specifically resistant against a t …
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H. Eide MB, et al. Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241276 Review.
Clonal deletion of thymocytes as a tumor escape mechanism.
Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Lauritzsen GF, et al. Int J Cancer. 1998 Oct 5;78(2):216-22. doi: 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8. Int J Cancer. 1998. PMID: 9754655 Free article.
35 results